<DOC>
	<DOCNO>NCT01491139</DOCNO>
	<brief_summary>The aim study find safe dose best dosing schedule olaparib give combination cisplatin base chemoradiotherapy ( CRT ) patient locally advanced head neck cancer . The dose decide part study become recommend dose randomised Phase II trial .</brief_summary>
	<brief_title>Phase I Study Olaparib With Cisplatin Based Chemoradiotherapy Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This dose escalate Phase I/II trial evaluate safety tolerability addition olaparib CRT high risk locally advanced human papillomavirus ( HPV ) negative Squamous Cell Carcinoma Head Neck ( HNSCC ) . A fixed dose weekly cisplatin intensity-modulated radiation therapy ( IMRT ) use , dose olaparib escalate consecutive day dose level duration increase cohort . This Phase I trial ass olaparib , poly ADP ribose polymerase ( PARP ) inhibitor tolerate added standard chemoradiotherapy treatment . Patients recruit site UK . A placebo control , randomise Phase II trial follow recommend dose schedule olaparib establish .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm high risk , locally advanced HNSCC patient ( TNM staging : Tany N2/3 M0 , bulky T3 T4 Nany M0 ) would normally offer cisplatinbased radical chemoradiotherapy Estimated life expectancy least 12 week WHO performance status 0 1 Aged â‰¥18 year age Adequate major organ function Willing use contraception duration trial treatment six month completion treatment Able give informed consent Willing able comply protocol duration study Head &amp; neck cancer follow type : Nasopharyngeal paranasal sinus tumour , Oral squamous cell carcinoma ( tumours oral cavity ) , Human Papilloma Virus positive oropharyngeal tumour ( tonsillar tongue base tumour ) Confirmed distant metastatic disease Previous chemotherapy radiotherapy treatment HNSCC tumour Previous therapy PARP inhibitor Preexisting gastrointestinal disorder may interfere delivery absorption olaparib Grade 3 4 peripheral neuropathy Significant hearing difficulty tinnitus ( deaf patient include ) The current use drug know inhibit induce CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Biomarkers , pharmacological</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Genetic Markers</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Poly ( ADP-ribose ) Polymerases</keyword>
	<keyword>AZD 2281</keyword>
	<keyword>Radiotherapy , Intensity-Modulated</keyword>
	<keyword>Head Neck</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>SCC</keyword>
</DOC>